OR WAIT 15 SECS
© 2020 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2020 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
June 01, 2008
Comparative drug analysis aims to address costs and value as candidates eye curbs on drug spending.
Insurty gets ready to meet FDA’s requirement that regulatory submissions be in eCTD format.
Just like pharma, biotech companies need clinical research organizations too, but are their needs different?
A new initiative aims to identify new methods to make the clinical trials process more efficient and effective.
Acceptance of data ambiguity by the industry is the key to adaptive design adoption and use.
A new project focuses on developing Africa's legal and regulatory framework for health research.
With help from technology, adaptive trials can enhance dose selection and reduce time between phases.
Chris Bode, PhD, vice president of corporate development for Absorption Systems, explains the impact of in vitro models relative to the Critical Path Initiative.
In the European Union, regulators are agonizing over more than just clinical trials.
DIA expands into India with a new office and advisory council.
Industry news tidbits from around the world.
Low costs, a rich patient base, and strong talent pool characterize Africa's most populated country.
Why this age-old industry staple is missing the mark for many and what can be done to remedy the situation.
Survey uncovers current market and future directions for the European clinical trials industry.
Industry news focusing on the people and organizations who work in the clinical trials profession.
How one workload study measured tasks, time, and resources necessary to run a cancer clinical trial today.
Integrating clinical trials and named patient programs to provide global access to drugs before approval.
A call to sponsors to rethink the role of ECGs in drug development and the use of central core labs.
CROs must adjust their practices to cater to small/mid-tier pharma instead of simply servicing big pharma.
A look at its early beginnings, where it is today, and what the future could hold.
Pilot test to rebrand clinical research shows promise as a way to build public trust and promote interest.